INT 2106
Alternative Names: INT-2106Latest Information Update: 15 Jan 2025
Price :
$50 *
At a glance
- Originator Interius BioTherapeutics
- Class CAR-NK cell therapies; CAR-T cell therapies; Gene therapies
- Mechanism of Action Gene transference; Natural killer cell modulators; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 07 Jan 2025 Preclinical trials in Autoimmune disorders in USA (IV) (Interius Pipeline, January 2025)
- 07 Jan 2025 Pharmacokinetics data from a preclinical study in Autoimmune disorders released by Interius Bio (Interius Bio Pipeline, January 2025)